Phase I/II Trial With Sorafenib in Combination With RAD001 Administered Orally in Patients With Advanced Solid Tumors, Selected on the Base of Molecular Targets.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Oct 2010 New trial record